The Lewin Group to Provide Analysis and Program Support for the Obstetric and Pediatric Pharmacology Branch of the NICHD, National Institutes of Health
January 07, 2009
Federal engagement supports key elements of children’s health program to improve the development, safety and efficacy of pharmaceuticals for children
Falls Church, VA – January 7, 2009 – The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded a two-year contract to The Lewin Group, one of the nation’s leading health care and human services consulting organizations. The Lewin Group will provide scientific and technical support to help NICHD accomplish the goals of the Best Pharmaceuticals for Children Act of 2007 (BPCA) reauthorization.
The BCPA program is critical to identifying new approaches in children’s disease treatment and management, such as pediatric therapeutics enhancement, medical device improvement and drug and vaccine development. The Lewin Group’s program management skills, combined with technical and scientific support capabilities, will enable BPCA program implementation through workshops, symposia, independent data analysis and the enlistment of key pediatric medical researchers.
“This engagement underscores The Lewin Group’s commitment to supporting federal government agencies’ missions and programs,” said Lewin Group Executive Vice President Lisa Chimento. “We’re excited that our contribution can help the NICHD’s efforts toward improving the lives of millions of children.”
About The Lewin Group
The Lewin Group, an Ingenix company, is a premier national health care and human services consulting firm with more than 35 years of experience finding answers and solving problems for leading organizations in the public, non-profit and private sectors.